Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (26718)	12/1/1998 4:11:00 PM
From: Cacaito	Read Replies (1) \| Respond to of 32384

Condylomata acuminata is a tumor-like viral lesion (KS is also viral induced) current treatments freezing, laser, and caustic type chemicals in order of frequency. It could become an alternative treatment. (Condylomata lata is a syphilis lesion probably not the one refer by D, Robinson). Molluscum contagiosum cause by a poxvirus, common in children and most common treatment is observation, many treated lesions could scar the skin, if Panretin does not produces scars it will be a good alternative. Skin hemangiomas and pyogenic granuloma could theoretically respond to panretin. All this lesions are much more common than KS, probably bigger markets.

To: Henry Niman who wrote (26718)	12/1/1998 7:55:00 PM
From: Cheryl Galt	Read Replies (1) \| Respond to of 32384

Henry, Thanks for reporting on this morning's conference call. I appreciate all your details. Hopefully, Panretin gel will provide substantial and fairly non-toxic relief for many different kinds of lesions. Hopefully, Ligand will have its first marketable drug in time for Christmas -- a cause for a well-deserved celebration. Cheryl ----------- PS I'm feeling sad at the loss of Seattle's Public Schools Superintendent John Stanford. He died of acute myelogenous leukemia early Saturday morning, having battled it since April. In that time, while continuing to work, he went through three rounds of chemo, then a stem cell transplant, then started yet another round chemo after the cancer again recurred. Too bad one of Ligand's less toxic molecules wasn't available to help him. John Stanford was too good to lose. seattletimes.com